Design, Synthesis, and Mechanistic Anticancer Evaluation of New Pyrimidine-Tethered Compounds
Authors:
- Farida ReymovaFRFarida Reymova
- Belgin SeverBelgin Sever
- Edanur TopalanETEdanur Topalan
- Canan Sevimli-GurCSCanan Sevimli-Gur
- Mustafa CanMCMustafa Can
- Amaç Fatih TuyunATAmaç Fatih Tuyun
- Faika BaşoğluFBFaika Başoğlu
- Abdulilah EceAEAbdulilah Ece
- Masami OtsukaMOMasami Otsuka
- Mikako FujitaMikako Fujita
- Hasan DemirciHasan Demirci
- Halilibrahim CiftciHalilibrahim Ciftci
Open Access
- 19 February 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (2) , 270
Abstract
Background: Despite recent breakthroughs in cancer treatment, non-small cell lung cancer (NSCLC) and breast cancer remain major causes of death from all malignancies. The epidermal growth factor receptor (EGFR) is an important mediator of the pathways involved in cell proliferation, apoptosis, and angiogenesis. Thus, its overexpression triggers several types of cancer, including NSCLC and breast cancer. Methods: In the current study, we synthesized new pyrimidine-tethered compounds (chalcone derivative (B-4), pyrazoline–carbothioamide (B-9), and pyrazoline–thiazole hybrids (BH1-7)). These compounds were then tested for cytotoxicity against A549 NSCLC and MCF-7 breast cancer cells. Results: Of these, B-4 displayed significant cytotoxicity against both cells (IC50 = 6.70 ± 1.02 µM for MCF-7; IC50 = 20.49 ± 2.7 µM for A549) compared to the standard agent lapatinib (IC50 = 9.71 ± 1.12 µM for MCF-7; IC50 = 18.21 ± 3.25 µM for A549). The anticancer potential of B-4 between Jurkat leukemic T cells and peripheral blood mononuclear cells (PBMCs) (healthy) was found to be selective. Mechanistically, 11.9% and 10.2% of A549 and MCF-7 cells treated with B-4, respectively, underwent apoptosis and B-4 produced 46% EGFR inhibition at a concentration of 10 μM. The B-4/EGFR complex obtained after induced fit docking was subjected to 300 ns of molecular dynamics simulation, which confirmed the stability of the complex in a mimicked biological environment. On the other hand, B-4 was shown to have drug-like properties by in silico pharmacokinetic estimation. Conclusions: B-4 is an EGFR inhibitor and apoptosis inducer for future NSCLC and breast cancer studies.Keywords
Funding Information
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu (122Z775)
This publication has 73 references indexed in Scilit:
- Epidermal growth factor receptor inhibitors as potential anticancer agents: An update of recent progressBioorganic Chemistry, 2021
- Design, synthesis and investigation of the mechanism of action underlying anti-leukemic effects of the quinolinequinones as LY83583 analogsBioorganic Chemistry, 2021
- Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAFV600E kinasesBioorganic Chemistry, 2021
- Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancerBreast Cancer Research and Treatment, 2020
- EGFR inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and docking studies of novel xanthine derivatives carrying chalcone moiety as hybrid moleculesBioorganic Chemistry, 2019
- Synthesis and anti-proliferative activity of some new quinoline based 4,5-dihydropyrazoles and their thiazole hybrids as EGFR inhibitorsBioorganic Chemistry, 2019
- Emerging functions of the EGFR in cancerMolecular Oncology, 2017
- The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancerCancer and Metastasis Reviews, 2016
- Mechanisms of resistance to EGFR tyrosine kinase inhibitorsActa Pharmaceutica Sinica B, 2015
- New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studiesBioorganic & Medicinal Chemistry, 2006